NfX Bio led the financing which will bolster the company’s development of programmable ribonucleic acid (RNA)-based therapeutics utilising molecular RNA sensors for precise drug delivery. The funding round
The product, which received approval from the US Food and Drug Administration in April 2024, is now available for direct distribution to states and municipalities nationwide. Naloxone HCI
The company said it aims to achieve this target by registering growth in its current portfolio in biopharmaceuticals, oncology, and rare diseases. The effort also includes the launch
This marks the first biosimilar launched under the strategic partnership between the two companies. SIMLANDI has been approved by the US Food and Drug Administration (FDA) as the
With this agreement, IRBM will be able to leverage CRISPR/Cas9 technology to advance its drug discovery processes. The editing technology will also be integrated into the comprehensive drug
TWYNEO is claimed to be the first and only US Food and Drug Administration (FDA)-approved fixed-dose cream which combines tretinoin and benzoyl peroxide for treating acne vulgaris in
The latest milestone means that the company’s microbial cleanrooms are now qualified for the production of cGMP microbial biologic drugs. The validation of Scorpius’ microbial cleanrooms has already
The collaboration will combine FogPharma’s Helicon peptide platform with ARTBIO’s AlphaDirect platform to create targeted therapies using the 212Pb isotope. The companies will jointly develop HEARTs against multiple
The company initially acquired the site in 2022 and extensively renovated it. The Bronx facility is equipped with latest technology and marks a significant investment by PharmaLogic in
The funding attracted a diverse group of new investors, including Cormorant Asset Management, SymBiosis, Surveyor Capital, Walleye Capital, Laurion Capital Management, Tetragon Financial Group, LG Technology Ventures, Cantor
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.